Dupilumab is prescribed for treating moderate-to-severe atopic dermatitis in adult patients who do not respond to topical treatments or cannot tolerate standard therapies. It acts as an ...

In 2017, the FDA approved dupilumab to treat dermatitis when prescription skin creams didn’t help. In 2018, the FDA approved it to treat asthma in people aged 12 or older. Researchers kept ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

The FDA has approved these four biologics to treat atopic dermatitis: dupilumab, lebrikizumab, nemolizumab, and tralokinumab. They are all types of biologics called monoclonal antibodies.

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

For the study, investigators evaluated children aged 6 months to 5 years with moderate-to-severe atopic dermatitis who had been treated with either dupilumab or a placebo. Researchers compared ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

Dupilumab was associated with higher odds ... as another effective biologic medication for treating atopic dermatitis. Although binary efficacy outcomes favored dupilumab, the differences in ...

open-label trial assessing Dupixent® (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. These are the first clinical trial results for Dupixent in ...